These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11374737)

  • 1. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment.
    Núñez Martínez O; Ripoll Noiseux C; Carneros Martín JA; González Lara V; Gregorio Marañón HG
    Am J Gastroenterol; 2001 May; 96(5):1665-6. PubMed ID: 11374737
    [No Abstract]   [Full Text] [Related]  

  • 2. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
    Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract]   [Full Text] [Related]  

  • 3. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.
    Jain VV; Evans T; Peterson MW
    Respir Med; 2006 Jul; 100(7):1291-3. PubMed ID: 16545951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 6. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

  • 7. Tuberculosis and treatment with infliximab.
    Zhang Z; Correa H; Bégué RE
    N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859880
    [No Abstract]   [Full Text] [Related]  

  • 8. [Development of tuberculosis after treatment with the TNF-alpha inhibitor infliximab].
    Dahl M; Ravn P
    Ugeskr Laeger; 2005 Jan; 167(5):527-8. PubMed ID: 15745179
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Triantafillidis et al.--Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment.
    Fefferman DS; Alsahli M; Lodhavia PJ; Shah SA; Farrell RJ
    Am J Gastroenterol; 2001 Aug; 96(8):2510-1. PubMed ID: 11513207
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody.
    Kohara MM; Blum RN
    Clin Infect Dis; 2006 Mar; 42(5):733-4. PubMed ID: 16447129
    [No Abstract]   [Full Text] [Related]  

  • 11. [Practice guidelines in gastroenterology. Use of anti-TNF agents in inflammatory bowel disease. European guide 2001-2003].
    Rom J Gastroenterol; 2002 Mar; 11(1):68-71. PubMed ID: 12219731
    [No Abstract]   [Full Text] [Related]  

  • 12. [Selective TNF-alpha inhibition in Crohn disease. Emergency help in problem cases].
    MMW Fortschr Med; 2001 May; 143(18):52. PubMed ID: 11387713
    [No Abstract]   [Full Text] [Related]  

  • 13. [Disseminated tuberculosis following infliximab therapy for Crohn disease: a case report].
    Bouchentouf R; Yasser Z; Aitbenasser MA
    Rev Pneumol Clin; 2014 Dec; 70(6):366-9. PubMed ID: 25131370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH; Galle PR; Neurath MF
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract]   [Full Text] [Related]  

  • 15. [Meningitis due to Listeria monocytogenes as a complication of infliximab therapy].
    Joosten AA; van Olffen GH; Hageman G
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1470-2. PubMed ID: 12908351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab-induced palmoplantar pustulosis in a patient with crohn disease.
    Sladden MJ; Clarke PJ; Wettenhall J
    Arch Dermatol; 2007 Nov; 143(11):1449. PubMed ID: 18025378
    [No Abstract]   [Full Text] [Related]  

  • 18. Infliximab-induced acne: report of two cases.
    Bassi E; Poli F; Charachon A; Claudepierre P; Revuz J
    Br J Dermatol; 2007 Feb; 156(2):402-3. PubMed ID: 17223901
    [No Abstract]   [Full Text] [Related]  

  • 19. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.